Status:
COMPLETED
14-day Quadruple Therapy Versus Triple Therapy in HP Eradication
Lead Sponsor:
mohamed bouchoucha
Conditions:
Gastritis H Pylori
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
In this prospective randomized-controlled study, treatment-naive H. pylori-infected patients are randomized to receive either standard triple therapy or sequential therapy. The aim is to compare the e...
Detailed Description
This study includes male and female patients aged between 18 and 65, with documented Hp infection and who have had no previous eradication treatment.The diagnosis of Hp infection was made through an a...
Eligibility Criteria
Inclusion
- patients aged between 18 and 65, with documented Hp infection.
Exclusion
- are excluded patients:
- With Cirrhosis.
- With Renal failure (serum creatinine\> 120 µmol / L).
- Having complicated peptic ulcer (stenosis or hemorrhage or perforation) in an acute phase.
- Having severe psychiatric disorders.
- Having had gastric surgery in their history.
- Having already received an HP eradication treatment.
- Having received an antibiotic within the last two weeks.
- Who are allergic to one of the antibiotics used in the anti-Hp cure.
- Who are drug addicted.
Key Trial Info
Start Date :
February 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 5 2020
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT04769583
Start Date
February 10 2019
End Date
March 5 2020
Last Update
February 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fattouma Bourguiba Hospital
Monastir, Tunisia